Hiroki Fujikawa
Overview
Explore the profile of Hiroki Fujikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamamoto Y, Takeuchi I, Shimizu H, Fujikawa H, Toda M, Miyata E, et al.
J Gastroenterol Hepatol
. 2024 Nov;
40(1):123-132.
PMID: 39496363
Background And Aim: Only a few studies have reported the long-term effects of ustekinumab on pediatric Crohn's disease. Therefore, this study aimed to describe the long-term clinical and endoscopic outcomes...
2.
Hirai Y, Sakurai J, Yoshida S, Kikuchi T, Mitsuhashi T, Miyake T, et al.
J Dermatol
. 2024 Jun;
51(8):1037-1049.
PMID: 38874430
Brentuximab vedotin (BV), a conjugate of anti-CD30 antibody and monomethyl auristatin E, has emerged as a promising treatment option for refractory CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large-cell...
3.
Takei S, Hayashi R, Tomii K, Deguchi T, Fujikawa H, Shinkuma S, et al.
J Dermatol
. 2023 Oct;
51(1):125-129.
PMID: 37789597
Infancy associated eosinophilic pustular folliculitis (I-EPF) is a clinical variant of EPF that develops in childhood. Previous studies have suggested that I-EPF exhibits clinical and histological differences distinct from other...
4.
Ishige T, Shimizu T, Watanabe K, Arai K, Kamei K, Kudo T, et al.
J Gastroenterol
. 2023 Feb;
58(4):431-432.
PMID: 36763141
No abstract available.
5.
Ishige T, Shimizu T, Watanabe K, Arai K, Kamei K, Kudo T, et al.
J Gastroenterol
. 2023 Jan;
58(2):135-157.
PMID: 36629948
Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation...
6.
Fujikawa H, Shimizu H, Nambu R, Takeuchi I, Matsui T, Sakamoto K, et al.
Clin Immunol
. 2022 Dec;
246:109203.
PMID: 36503158
STXBP2, encoding syntaxin-binding protein 2, is involved in intracellular organelle trafficking and is associated with familial hemophagocytic lymphohistiocytosis type 5. Although STXBP2 mutations reportedly cause monogenic inflammatory bowel disease, the...
7.
Usami M, Takeuchi I, Kyodo R, Hirano Y, Kashiwagi K, Fujikawa H, et al.
Intest Res
. 2022 Jun;
20(4):475-481.
PMID: 35686293
Background/aims: Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed in patients younger than 6 years, is a challenge for pediatric gastroenterologists. Although there have been reports regarding VEO-IBD...
8.
Sasaki J, Fujikawa H, Katsumi T, Saito Y, Yuki A, Kameyama H, et al.
J Dermatol
. 2021 Feb;
48(4):e198-e200.
PMID: 33580893
No abstract available.
9.
Saito Y, Fujikawa H, Takatsuka S, Abe R, Takenouchi T
Int J Clin Oncol
. 2020 Nov;
26(3):606-612.
PMID: 33175299
Background: Cutaneous squamous cell carcinoma (CSCC) is one of the most common skin cancers. Prognosis is favorable following surgical resection of early-stage disease, but the management of the metastatic disease...
10.
Shimagaki H, Yuki A, Kimura K, Yuki D, Fujikawa H, Shimizu N, et al.
J Dermatol
. 2020 Mar;
47(5):542-545.
PMID: 32173890
Botryomycosis is a rare chronic suppurative granulomatous infection caused by several genera of non-filamentous bacteria. The clinical and histopathological findings are similar to those of mycetoma caused by true fungi...